Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics

Mattern-Schain, Samuel I.; Fisher, Richard K.; West, P.; Grimsley, Lauren B.; Harris, Taylor; Grandas, Oscar H.; Best, Michael D.; Mountain, Deidra J.H.

doi:10.1016/j.chemphyslip.2018.12.009

Cited by 11 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that significant, dosedependent increase of efficacy and cell-type specific viability were observed by usage of diacylglycerol (DAG) and phosphatidylserine (PS), which could naturally influence vascular cell function. This method offered a natural strategy for high efficacy delivery of siRNA (Samuel et al, 2018)…”

Section: Involving In Usage Of Cationic Lipids In Most Of the Lipid-bmentioning

confidence: 99%

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA

Chen

Zhao

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

RNA interference (RNAi) technology has become a powerful tool in application of unraveling the mechanism of disease and may hold the potential to be developed for clinical uses. Small interfering RNA (siRNA) can bind to target mRNA with high specificity and efficacy and thus inhibit the expression of related protein for the purpose of treatment of diseases. The major challenge for RNAi application is how to improve its stability and bioactivity and therefore deliver therapeutic agents to the target sites with high efficiency and accuracy. PEGylated lipid-based delivery system has been widely used for development of various medicines due to its long circulating half-life time, low toxicity, biocompatibility, and easiness to be scaled up. The PEGylated lipid-based delivery system may also provide platform for targeting delivery of nucleic acids, and some of the research works have moved to the phases for clinical trials. In this review, we introduced the mechanism, major challenges, and strategies to overcome technical barriers of PEGylated lipid-based delivery systems for advanced target delivery of siRNA in vivo. We also summarized recent advance of PEGylated lipid-based siRNA delivery systems and included some successful research works in this field.

show abstract

Section: Involving In Usage Of Cationic Lipids In Most Of the Lipid-bmentioning

confidence: 99%

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA

Chen

Zhao

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In spite of obtaining powerful and effective nanovehicles based on formulating lipid molecules and siRNAs, liposomes and niosomes85 have been properly tuned in order to promote targeted delivery in specific organs and tissues. This strategy has enabled the preparation of unique lipid-based platforms bearing the arginine-glycine-aspartic acid (RGD) peptide95 or decorated with an octa-arginine (R8) cell-penetrating peptide (CPPs) 96. These two strategies have confirmed increased particle stability, biocompatibility, and good siRNA therapeutic response without affecting remarkably cellular viability.…”

Section: Delivery Systemsmentioning

confidence: 99%

<p>Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach</p>

Chalbatani¹,

Dana²,

Gharagouzloo³

et al. 2019

IJN

188

View full text Add to dashboard Cite

Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment.

show abstract

“…Because the ME was placed above the cells for gel formation in the medium (and not in direct contact with the cells), we acknowledge the possibility of gel-related stress, interference with gas exchange, and release of components in the medium, affecting cell viability and migration. MEs have been demonstrated to influence cell and tissue viability depending on their composition since surfactants, lipids, and cosolvents may affect membrane fluidity and integrity, interfere with signaling pathways, and trigger the release of cytokines. ,,,,,− Although less studied, nanocarrier components might also affect cell migration. Short-chain triglycerides have been suggested to reduce cell viability and migration, , while a study carried out by Shin et al demonstrated that liposomes inhibited the migration of SK-BR-3 cells by approximately 16.5% …”

Section: Discussionmentioning

confidence: 99%

Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development

et al. 2021

View full text Add to dashboard Cite

The need of pharmacological strategies to preclude breast cancer development motivated us to develop a non-aqueous microemulsion (ME) capable of forming a depot after administration in the mammary tissue and uptake of interstitial fluids for prolonged release of the retinoid fenretinide. The selected ME was composed of phosphatidylcholine/tricaprylin/propylene glycol (45:5:50, w/w/w) and presented a droplet diameter of 175.3 ± 8.9 nm. Upon water uptake, the ME transformed successively into a lamellar phase, gel, and a lamellar phase-containing emulsion in vitro as the water content increased and released 30% of fenretinide in vitro after 9 days. Consistent with the slow release, the ME formed a depot in cell cultures and increased fenretinide IC50 values by 68.3- and 13.2-fold in MCF-7 and T-47D cells compared to a solution, respectively. At non-cytotoxic concentrations, the ME reduced T-47D cell migration by 75.9% and spheroid growth, resulting in ∼30% smaller structures. The depot formed in vivo prolonged a fluorochrome release for 30 days without producing any sings of local irritation. In a preclinical model of chemically induced carcinogenesis, ME administration every 3 weeks for 3 months significantly reduced (4.7-fold) the incidence of breast tumors and increased type II collagen expression, which might contribute to limit spreading. These promising results support the potential ME applicability as a preventive therapy of breast cancer.

show abstract

Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics

Cited by 11 publications

References 38 publications

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA

<p>Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach</p>

Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development

Contact Info

Product

Resources

About